Neuroendocrine Neoplasia Neuroendocrine Tumor
Conditions
Brief summary
Disease control rate (DCR) 6 months after treatment start (Complete Response (CR) + Partial Response (PR) + Stable Disease (SD))
Detailed description
Disease control rate 3 and 12 months after treatment start, Objective response rate (ORR) 3 months after treatment start and best objective response rate, Progression free survival (PFS) and overall survival (OS), Time on drug (TOD), EORTC QLQ-C30 Quality of Life Questionnaire monthly for 12 months after treatment start and after 15 months, Serious adverse events and adverse events, Data Safety Monitoring Board (DSMB)
Interventions
Sponsors
Universitaetsmedizin Goettingen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease control rate (DCR) 6 months after treatment start (Complete Response (CR) + Partial Response (PR) + Stable Disease (SD)) | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate 3 and 12 months after treatment start, Objective response rate (ORR) 3 months after treatment start and best objective response rate, Progression free survival (PFS) and overall survival (OS), Time on drug (TOD), EORTC QLQ-C30 Quality of Life Questionnaire monthly for 12 months after treatment start and after 15 months, Serious adverse events and adverse events, Data Safety Monitoring Board (DSMB) | — |
Countries
Austria, Germany
Outcome results
None listed